Blog Unraveling the Power of Germline Clinico-Genomic Data: A Game Changer in Pharma's Drug Development Lifecycle
Press ReleasesHelix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases to Advance Drug Discovery and DevelopmentMarch 18, 2025
Press ReleasesHelix Unveils Groundbreaking Real-World Insights at the ACMG Annual Clinical Genetics Meeting, Driving Clinical Care ForwardMarch 13, 2025
Press ReleasesHelix Launches World's Largest Clinico-Genomic Cohort of GLP-1 Agonist Treated PatientsFebruary 3, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
2Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
3Published ResearchPopulation genomic screening leads to improved lipid management in patients with familial hypercholesterolemiaMarch 19, 2025
4Published ResearchUnderestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetesNovember 21, 2024
5Published ResearchHelix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse PopulationsNovember 13, 2024
Press ReleasesJun 28, 2022Memorial Hermann and Helix Partner on a Population Genomics Initiative Aimed at Driving Precision Health Care for Texans
NewsJun 22, 2022Why Are There So Many Omicron Subvariants—And What Can They Tell Us About the Future of the Pandemic?Health Magazine